How does STERIS (STE) make money?

STERIS (STE) generates revenue primarily from Product, which accounted for 51.6% of total revenue in TTM through Q1 2026. The company reported $5.94B in revenue and converted 13.2% of it into net profit, equivalent to roughly $782.40M in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of STERIS (STE)?

STERIS (STE) reported a gross profit margin of 44.2% in TTM through Q1 2026, equivalent to $2.63B in gross profit on $5.94B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of STERIS (STE)?

STERIS (STE) reported an operating profit margin of 18.6% in TTM through Q1 2026, equivalent to $1.10B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of STERIS (STE)?

STERIS (STE) reported a net profit margin of 13.2% in TTM through Q1 2026, equivalent to $782.40M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is STERIS (STE) profitable?

Yes. STERIS (STE) reported $782.40M in net income for TTM through Q1 2026, with a net profit margin of 13.2%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does STERIS (STE) invest in research and development?

STERIS (STE) invested $112.90M in research and development during TTM through Q1 2026, roughly 1.9% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does STERIS (STE) spend on capital expenditures?

STERIS (STE) spent $369.00M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 6.2% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does STERIS (STE) generate?

STERIS (STE) generated $972.40M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 16.4%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of STERIS (STE)?

STERIS (STE) had an effective tax rate of 25% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of STERIS (STE)?

STERIS (STE) reports revenue across 2 reportable product segments, led by Product at 51.6% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does STERIS (STE) generate most of its revenue?

UNITED STATES is the largest geographic market for STERIS (STE), accounting for 73% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How STERIS Makes Money: 2026 Visual Revenue Map

STERIS (STE) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 29, 2026).

STERIS (STE) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for STERIS (STE) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Product	$3.06B	51.6%
Service	$2.88B	48.4%
Total	$5.94B	100%

Product$3.06B
Service$2.88B
Total$5.94B

STERIS (STE) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for STERIS (STE), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$4.33B	73%
Other foreign locations	$1.49B	25.2%
IRELAND	$108.50M	1.8%
Total	$5.94B	100%

UNITED STATES
Other foreign locations
IRELAND
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, STERIS (STE) reports revenue across 2 operating segments; the largest segment was Product at 51.6%, followed by Service (48.4%). Separately, by end-market geography, UNITED STATES accounted for 73% of revenue, followed by Other foreign locations (25.2%) and IRELAND (1.8%).

Frequently asked questions

Data & methodology

STERIS (STE) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation